Condition: Solid Tumor · Sponsor: Biohaven Therapeutics Ltd.
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors
This description comes directly from the study's public registry record.
Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com
Always discuss trial participation with your own doctor first.
| Site-111 | Newport Beach, California, United States | Recruiting |
| Site-107 | Denver, Colorado, United States | Recruiting |
| Site-108 | Lake Mary, Florida, United States | Withdrawn |
| Site-121 | Miami, Florida, United States | Recruiting |
| Site-118 | Orlando, Florida, United States | Recruiting |
| Site-120 | Ann Arbor, Michigan, United States | Recruiting |
| Site-110 | Detroit, Michigan, United States | Recruiting |
| Site-115 | Durham, North Carolina, United States | Recruiting |
| Site-122 | Cleveland, Ohio, United States | Recruiting |
| Site-112 | Myrtle Beach, South Carolina, United States | Recruiting |
| Site-116 | Nashville, Tennessee, United States | Recruiting |
| Site-103 | Austin, Texas, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06874335